Burasakarn Pipit, Thienhiran Anuparp, Hongjinda Sermsak, Fuengfoo Pusit
Division of HPB Surgery, Department of Surgery, Phramongkutklao Hospital, Thung Phaya Thai, Ratchathewi, Bangkok, 10400, Thailand.
Asian J Surg. 2022 Jan;45(1):33-38. doi: 10.1016/j.asjsur.2021.05.005. Epub 2021 May 26.
Extensive surgery is the mainstay treatment for gallbladder cancer and offers a long-term survival benefits to the patients. However, the optimal extent of surgery remains debatable. We aimed to perform a meta-analysis of hepatectomy and no hepatectomy approaches in patients with T2 gallbladder cancer. We searched the following electronic databases for systematic literature: PubMed, Google Scholar, and the Cochrane Library. We selected studies that compared patients with T2 gallbladder cancer who underwent hepatectomy with those who did not. While the long-term overall survival (OS) and disease-free survival (DFS) were the primary outcomes, perioperative morbidity and mortality were the secondary outcome. We analysed over 18 studies with 4,587 patients. Of the total patients, 1,683 and 1,303 patients underwent hepatectomy and no hepatectomy, respectively. The meta-analysis revealed no significant difference between the hepatectomy and no hepatectomy groups, in terms of the overall morbidity (risk ratio [RR] = 1.85, 95% confidence interval [CI] = 0.66-5.20) and 30-day mortality (RR = 0.9, 95% CI = 0.1-8.2). The results were comparable in terms of the OS (RR = 0.76, 95% CI = 0.57-1.01), (HR = 0.74, 95% CI = 0.49-1.12), and DFS (RR = 0.99, 95% CI = 0.88-1.11). In conclusion, the perioperative and long-term outcomes of hepatectomy and no hepatectomy approaches were comparable. Hepatectomy may not be required in T2 gall bladder cancer if the preoperative evaluation confirms the depth of the tumour in the perimuscular connective tissue and the intraoperative frozen sections confirm microscopic negative margins. Likewise, for those whom gall bladder cancer was diagnosed from the pathological report after simple cholecystectomy, further hepatectomy may not necessary.
广泛手术是胆囊癌的主要治疗方法,能为患者带来长期生存益处。然而,手术的最佳范围仍存在争议。我们旨在对T2期胆囊癌患者的肝切除术和非肝切除术方法进行荟萃分析。我们在以下电子数据库中检索系统文献:PubMed、谷歌学术和考克兰图书馆。我们选择了比较接受肝切除术的T2期胆囊癌患者和未接受肝切除术患者的研究。长期总生存(OS)和无病生存(DFS)是主要结局,围手术期发病率和死亡率是次要结局。我们分析了18项以上包含4587例患者的研究。在全部患者中,分别有1683例和1303例患者接受了肝切除术和未接受肝切除术。荟萃分析显示,肝切除术组和非肝切除术组在总体发病率(风险比[RR]=1.85,95%置信区间[CI]=0.66 - 5.20)和30天死亡率(RR=0.9,95% CI=0.1 - 8.2)方面无显著差异。在OS(RR=0.76,95% CI=0.57 - 1.01)、(HR=0.74,95% CI=0.49 - 1.12)和DFS(RR=0.99,95% CI=0.88 - 1.11)方面结果相似。总之,肝切除术和非肝切除术方法的围手术期及长期结局相似。如果术前评估确定肿瘤在肌周结缔组织中的深度,且术中冰冻切片证实切缘镜下阴性,则T2期胆囊癌可能无需进行肝切除术。同样,对于那些在单纯胆囊切除术后病理报告确诊为胆囊癌的患者,可能无需进一步行肝切除术。